Journal Articles, 2008

Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, Shaw BE, McMillan A, Gonzalez J, Ho A, Mufti GJ and Pagliuca A : Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol, 141 235-243, 2008.
Madrigal A and Shaw BE : Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells Mol Dis, 40 40-43, 2008.
Mayor NP, Shaw BE, Madrigal JA and Marsh SGE : No impact of NOD2/CARD15 on outcome after SCT - A reply. Bone Marrow Transplantation, (in press), 2008.
Shaw BE and Russell NH : Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant, 41 495-503, 2008.
Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH and Liu Yin JA. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. Br J Haematol, (in press), 2008.